The next-gen digital inhaler provides accurate digital dose counter along with low dose warning indicator to track patience adherence
Glenmark Pharmaceuticals has announced launch of ‘Digihaler,’ a Digital Dose Inhaler (DDI). This next-gen inhaler provides accurate digital dose counter along with low dose warning indicator to enable asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy.
The device has DDI enabled with electronic dose metered kit which ensures ‘Precise’ or ‘Accurate’ delivery of dosage for assured benefits. The revolutionary Digital Dose Inhaler – DDI offers several benefits like low dose display forewarning the patient about the impending end of the ‘recommended’ doses, end dose display, so device can be replaced with a new one’ and ‘Tail-Off’ phenomenon.